Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22001211 | 0.89 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL23347753 | 0.88 | HRH3 (0.32) | MEN1KMT2A | |
| SCHEMBL21316728 | 0.86 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23347870 | 0.84 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22388964 | 0.84 | MEN1 (0.34) | MEN1KMT2AKDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL408364 | 0.83 | MEN1 (0.33) | MEN1KMT2AKDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL22001203 | 0.75 | — | — | |
| SCHEMBL22389366 | 0.74 | — | — | |
| SCHEMBL23347868 | 0.72 | — | — | |
| SCHEMBL23344665 | 0.72 | MEN1 (0.32) | MEN1KMT2AKDM4EL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | MEN1 1532/4885KMT2A 3958/4885KDM4E 4750/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | MEN1 1532/4885KMT2A 3958/4885KDM4E 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.